Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
mBio. 2023 Dec 19;14(6):e0256523. doi: 10.1128/mbio.02565-23. Epub 2023 Nov 8.
During infectious disease emergencies, it may be necessary to deploy new therapies without conclusive evidence for their effectiveness. During the SARS-CoV-2 pandemic, several countries used registries to track the use of COVID-19 convalescent plasma (CCP). Those registries provided evidence that CCP was effective when used early and with high titer.
在传染病紧急情况下,可能需要部署新的疗法,而这些疗法的有效性尚无定论。在 SARS-CoV-2 大流行期间,一些国家使用登记处来跟踪 COVID-19 恢复期血浆(CCP)的使用情况。这些登记处提供的证据表明,CCP 在早期使用且滴度较高时是有效的。